Why Is It Harder for Black Americans to Access GLP-1 Drugs?

Black patients are about 20% less likely than white patients to access GLP-1 drugs, reflecting a century of medical bias and structural inequality.
The article notes that while GLP-1 receptor agonists (such as Ozempic) have become popular drugs for diabetes and weight loss, Black patients are about 20% less likely than white patients to access them, and people in higher-income communities are about 13% more likely than those in lower-income communities. This gap is not merely an economic barrier but stems from a century of medical bias: in the early 20th century, diabetes was called a "luxury disease," and the medical establishment long denied that Black people could get diabetes, turning it into a "silent killer" in the Black community. The 1985 Heckler Report formally acknowledged health disparities for the first time, but bias persisted in new forms. A 2009 study showed that under similar social conditions, the diabetes gap essentially disappeared, indicating that structural factors are key. The article emphasizes that old patterns are repeating in the GLP-1 era, with body image shame and economic barriers jointly affecting medication decisions; the NAACP calls for expanded Medicare and Medicaid coverage, but the fundamental antidote lies in addressing structural problems such as housing, food, and healthcare access.
GLP-1 receptor agonists (such as Ozempic) have become popular drugs for weight loss and diabetes treatment, but research shows that Black patients are significantly less likely than white patients to access these medications. Behind this lies not only economic barriers but also a century-long history of medical bias.
The Reality of the Diabetes Burden and Medication Gap
According to video data, nearly 40 million Americans have type 2 diabetes, with the prevalence among Black adults at about 12% compared to about 7% among white adults. This means that one in two Black Americans may have diabetes, compared to one in two white Americans. However, when researchers reviewed 26 studies across the United States, they found a recurring pattern: Black patients are about 20% less likely than white patients to receive newer diabetes drugs.

This gap is not an isolated phenomenon. The same research also shows that income level affects medication accessibility: people in communities with household incomes above $100,000 are about 13% more likely to access GLP-1 drugs than those in communities with incomes below $50,000. A clinician candidly stated in the video: "In our practice, people with higher socioeconomic status or who self-identify as white typically have easier access to these medications."
GLP-1 receptor agonists are a class of drugs that work by mimicking the body's natural glucagon-like peptide-1 (GLP-1) hormone. GLP-1 is secreted by the gut after eating and promotes insulin release, inhibits glucagon secretion, slows gastric emptying, and acts on the brain's appetite center to produce a feeling of satiety. GLP-1 receptor agonists (such as semaglutide/Ozempic, liraglutide, etc.) were initially developed for type 2 diabetes treatment, improving blood sugar control by enhancing these effects; subsequent research found that they also produce significant weight loss, leading to their widespread use for obesity treatment. These drugs typically require subcutaneous injection, with some formulations available orally, are expensive, and require long-term use—benefits to weight and blood sugar often fade after discontinuation, making sustained medication coverage and accessibility a focal point of public health discussion.
A Century of Bias: From "Luxury Disease" to "Black People Don't Get Diabetes"
To understand today's gap, one must look back at history. A century ago, diabetes was once considered a "Jewish disease." In 1870, Dr. Joseph Zagan noticed that more than a quarter of diabetes patients in a sanatorium were Jewish. By 1916, American diabetes specialist Elliot P. Jocelyn wrote: "Diabetes occurs among the Jewish race with proverbial frequency." In 1924, New York public health official Haven Emerson called diabetes "the great luxury disease."
As for Black Americans, the medical establishment at the time did not even believe they could get diabetes. The video mentions a shocking medical conference record: at a hospital in New Orleans, a doctor discussing a paper asked: "I would like to ask the author of the paper whether, among the Black people he noticed with diabetes, there was a significant admixture of white blood? The more white blood, the more nervous they are. I wonder if this matters." Another doctor insisted that the Black diabetes patients he saw were either misdiagnosed or must have had white blood.

This bias turned diabetes into a "silent killer" in the Black community. Even though insulin and dietary therapy were effective for most people, Black patients were long neglected.
"Luxury disease" was a popular term in early 20th-century medical literature for diabetes, reflecting the notion that diabetes was a "disease of civilization" afflicting the wealthy due to overeating and lack of physical labor. In 1924, New York public health official Haven Emerson used this term, attributing the disease to lifestyle and wealth. This framework seemed neutral but carried an implicit moral judgment: it placed responsibility for the disease on individual behavior and provided an excuse to ignore the disease burden among poor and minority populations. When the medical establishment believed that Black people "don't get diabetes," any cases found among Black people were considered misdiagnoses or the result of "mixed white blood," systematically obscuring the true prevalence and delaying diagnosis and treatment.
From Neglect to Acknowledgment: The Divide Between Data and Reality
In 1985, U.S. Secretary of Health and Human Services Margaret Heckler released the first task force report on the health of Black and minority populations, formally acknowledging the existence of health disparities for the first time. The report stated: "There is a continuing disparity in the burden of death and illness experienced by Black and other minority Americans as compared with our nation's population as a whole." This report directly led to the establishment of the Department of Health and Human Services Office of Minority Health.
However, bias did not disappear—it merely changed form. The video points out that when explaining diabetes differences among groups, the medical establishment focused on "behavior" for Black people, on "genetics" for Native Americans, and on "a combination of genetics and behavior" for Mexican Americans. One expert countered: "This seems to say that Black and brown people are to blame because of their lifestyle. But the truth is multifactorial—how genes are influenced by environment (housing insecurity, financial insecurity, food insecurity, safety, and access to healthy food and medical care), and these variables ultimately affect a person's health down to the DNA level."

A 2009 study provided strong evidence for this: when Black and white Americans lived under similar social conditions, the diabetes gap in national data essentially disappeared.
Health disparities refer to unfair and avoidable differences in disease burden, healthcare access, treatment quality, and health outcomes among different populations, typically measured by social factors such as race, ethnicity, income, and education. The 1985 Heckler Report was the first official federal document to systematically acknowledge minority health disparities in the United States; it spurred the creation of the Department of Health and Human Services Office of Minority Health and established a policy direction of using data monitoring and program interventions to narrow gaps. Health disparities differ from mere biological differences—their roots lie largely in social and structural factors such as housing, income, food security, and the distribution of medical resources. Understanding this concept helps distinguish "differences" from "inequities": the former is descriptive, while the latter demands policy intervention.
Old Patterns Repeat in the GLP-1 Era
Today, GLP-1 drugs are viewed by some as "miracle weight-loss tools" and "status symbols," but history is repeating itself. The video notes that insulin was once underprescribed in African American communities, and now GLP-1 drugs show the same accessibility gap.
Beyond economic barriers, body image shame has also become a factor in whether Black Americans choose GLP-1 drugs. One expert explained: "People feel shame about the idea of needing medication to help with weight loss and health improvement; they feel shame about needing long-term medication use; and finally, about how the medication will affect their physical appearance."
The civil rights organization NAACP is calling for Black Americans to have access to these diabetes drugs at lower prices, and describes Medicare and Medicaid coverage of these drugs as a critical first step toward expanding access to life-saving medications.

Medicare and Medicaid are the two major public health insurance programs in the United States. Medicare primarily covers people aged 65 and older, some younger people with disabilities, and patients with end-stage renal disease; Medicaid is jointly funded by the federal and state governments and covers low-income people, pregnant women, children, and some people with disabilities. The two programs have different rules for prescription drug coverage: Medicare Part D provides drug benefits through private plans, with price negotiation and coverage scope limited by federal regulations; Medicaid drug coverage is determined by each state but must comply with federal minimum requirements. GLP-1 drugs are expensive, and coverage is often restricted when used for obesity indications, so organizations like the NAACP view expanding coverage under these two programs as a key policy lever for lowering barriers to medication access in Black communities.
Beyond Drugs: The Antidote to Structural Problems
GLP-1 drugs are highly effective in treating diabetes, but the video emphasizes that benefits often fade after discontinuation, making sustained coverage critical. However, even equal prescription accessibility cannot help low-income communities that lack access to regular healthcare, nutritious food, or healthy lifestyles.
The true "antidote" requires addressing the structural and environmental factors that originally created these health disparities. As the video concludes: "More pharmaceutical solutions cannot fully solve the root problem." From denying that Black people could get diabetes, to acknowledging the gap, to today's unequal access to GLP-1 drugs, what the medical establishment needs is not just new drugs but also a clear understanding of a century of bias and structural change.
Related articles

Gemini 4 Hydrogen Released: A 2.5x Faster Everyday AI Model
Google releases Gemini 4 Hydrogen, claiming 2.5x the speed of Gemini 3.8 Flash, with four-tier thinking control, a million-token context, and Orchestrator multi-model collaboration. API pricing is $1.50 per million input tokens.

Gemini 4 Hydrogen Hands-On: Google's Fastest and Cheapest AI Model
Hands-on with Gemini 4 Hydrogen: the fastest, cheapest model in the Gemini 4 family. We break down the Carbon/Argon/Hydrogen split, API pricing traps, free-tier limits, and the cost trade-offs of four thinking levels—with a real bug-debugging demo.

Gemini 4 Hydrogen vs Sonnet Comparison Test: Uses Only 1% of Weekly Quota, Performance on Par
Hands-on test: Gemini 4 Hydrogen vs Sonnet on the same CRUD task—Hydrogen used only 1% weekly quota with comparable performance and better UI details, while Anthropic's model used 7%. Developer says daily tasks don't require expensive models.